Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Is it because they will be subtracting another soon? Needing depth in the secondary, The Packers are signing former Las Vegas cornerback Nate Hobbs to a four-year deal. Hobbs has often played the ...

Free agent cornerback Nate Hobbs is signing a four-year, $48 million deal with the Green Bay Packers, his agent, Gregg Linton, told ESPN's Jeremy Fowler. With the Packers landing Hobbs ...

GREEN BAY, Wis. (WBAY) - The Packers are signing former Raiders cornerback Nate Hobbs, according to a report from NFL Network’s Tom Pelissero. Pelissero reports it’s a four-year, $48 million ...

Nate Duffett is a writer for ClutchPoints and a sports junkie at heart, especially for the Boston sports scene. Whether it's covering the NHL, MLB, NBA, NFL, or College Football and Basketball ...

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in rival Eli Lilly also sold off. Find out more: New trial data showed the ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

An experimental obesity drug from Novo Nordisk resulted in 15.7% weight loss after 68 weeks of treatment — falling short of the company's expectations of 25% weight loss. The subcutaneous ...

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...

For eligible patients, health care providers can send Wegovy prescriptions directly to NovoCare Pharmacy. Novo Nordisk is providing direct-to-patient delivery of Wegovy ® (semaglutide) through the ...

Shares in Novo Nordisk fell on Monday on a second set of worse than expected trial results for the latest obesity drug from the manufacturer of blockbuster treatments Ozempic and Wegovy.